ENhance Initiation and Retention in Isoniazid Preventive Therapy (IPT) Care for HIV Study (ENRICH Study)

NACompletedINTERVENTIONAL
Enrollment

338

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

February 29, 2016

Study Completion Date

May 7, 2021

Conditions
HIVTuberculosis
Interventions
BEHAVIORAL

Combination intervention components

"The CIP will contain programmatic, structural, and psychosocial components, including:~1. use of a clinical algorithm by providers;~2. identification of HIV-infected family members eligible for IPT, using an ICAP-developed family care enrollment form (ICAP - International Center for AIDS Care and Treatment Programs);~3. review of monitoring data on IPT initiation and adherence during monthly multidisciplinary team meetings;~4. reimbursement of transportation costs for monthly clinic visits; and~5. real-time adherence support using IVR via mobile phones and trained Peer Educators."

DRUG

Isoniazid Prevention Therapy

Standard of care involves Isoniazid Prevention Therapy (IPT) - the administration of Isoniazid (INH) to individuals with latent infection with M. tuberculosis in order to prevent progression to active TB disease.

Trial Locations (10)

Unknown

Addis Ketema Health Center, Dire Dawa

Dire Dawa Health Center, Dire Dawa

Gende Gerada Health Center, Dire Dawa

Gende Kore Health Center, Dire Dawa

Goro Health Center, Dire Dawa

Legehare Health Center, Dire Dawa

Melka-Jebdu Health Center, Dire Dawa

Sabian Health Center, Dire Dawa

Arategna Health Center, Harar

Jinela Health Center, Harar

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Columbia University

OTHER

NCT01926379 - ENhance Initiation and Retention in Isoniazid Preventive Therapy (IPT) Care for HIV Study (ENRICH Study) | Biotech Hunter | Biotech Hunter